Gene expression analysis in human polymorphonuclear leukocytes stimulated by LPSs from nosocomial opportunistic pathogens

Innate Immunity

Volumn 21, Issue 8, 2015, Pages 802-812

  Ubagai, Tsuneyuki ^a   Nakano, Ryuichi ^a   Nakano, Akiyo ^a   Kamoshida, Go ^a   Ono, Yasuo ^a  

^a TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

LPS; MDRA; MDRP; polymorphonuclear leukocyte; RT PCR

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; CD14 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8 RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 1; TUMOR NECROSIS FACTOR ALPHA; LIPOPOLYSACCHARIDE; LIPOPOLYSACCHARIDE, ESCHERICHIA COLI O111 B4; TLR4 PROTEIN, HUMAN;

ACINETOBACTER BAUMANNII; ACYLATION; ARTICLE; BACTERIAL STRAIN; BONE MARROW CELL; CELL STIMULATION; CONTROLLED STUDY; ESCHERICHIA COLI; FEMALE; GENE EXPRESSION; GLYCOSYLATION; HUMAN; HUMAN CELL; MALE; MULTIDRUG RESISTANCE; NEUTROPHIL; NORMAL HUMAN; PSEUDOMONAS AERUGINOSA; RECEPTOR DOWN REGULATION; UPREGULATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; INNATE IMMUNITY; MICROBIOLOGY; OPPORTUNISTIC INFECTION; PHYSIOLOGY;

ACINETOBACTER BAUMANNII; GENE EXPRESSION REGULATION; HUMANS; IMMUNITY, INNATE; LIPOPOLYSACCHARIDES; NEUTROPHILS; OPPORTUNISTIC INFECTIONS; PSEUDOMONAS AERUGINOSA; TOLL-LIKE RECEPTOR 4;

EID: 84945178441     PISSN: 17534259     EISSN: 17534267     Source Type: Journal    
DOI: 10.1177/1753425915605892     Document Type: Article

References (49)

1. Gioannini TL, Weiss JP,. Regulation of interactions of Gram-negative bacterial endotoxins with mammalian cells. Immunol Res 2007; 39: 249-260.
2. Medzhitov R,. Approaching the asymptote: 20 years later. Immunity 2009; 30: 766-775.
3. Ellis TN, Kuehn MJ,. Virulence and immunomodulatory roles of bacterial outer membrane vesicles. Microbiol Mol Biol R 2010; 74: 81-94.
4. Ernest RK, Yi EC, Guo L, et al. Pseudomonas aeruginosa. Science 1999; 286: 1561-1565.
5. Sabra W, Lundsdorf H, Zeng AP,. Alterations in the formation of lipopolysaccharide and membrane vesicles on the surface of Pseudomonas aeruginosa PAO1 under oxygen stress conditions. Microbiology 2003; 149: 2789-2795.
6. http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/default.htm (last accessed 1 July 2015).
7. Leive L, Morrison DC,. Isolation of lipopolysaccharides from bacteria. Methods Enzymol 1972; 28: 254-262.
8. Ubagai T, Tansho S, Ito T, et al. Influences of aflatoxin B1 in reactive oxygen species generation and chemotaxis of human polymorphonuclear leukocytes. Toxicol in Vitro 2008; 22: 1115-1120.
9. Ubagai T, Koshibu Y, Koshio O, et al. Downregulation of immunomdulator gene expression in LPS-stimulated human polymorphonuclear leukocytes by the proton pump inhibitor lansoprazole. J Infect Chemother 2009; 15: 374-379.
10. Ubagai T, Nakano R, Kikuchi H, et al. Gene expression analysis of TREM1 and GRK2 in polymorphonuclear leukocytes as the surrogate biomarkers of acute bacterial infections. Int J Med Sci 2014; 11: 215-221.
11. Blander JM, Medzhitov R,. Regulation of phagosome maturation by signals from Toll-like receptors. Science 2004; 304: 1014-1018.
12. Sanjuan MA, Dillon CP, Tait SW, et al. Toll-like receptor signaling in macrophages links the autophagy pathway to phagocytosis. Nature 2007; 450: 1253-1257.
13. West AP, Brodssky IE, Rahner C, et al. TLR signaling augments macrophage bactericidal activity through mitochondrial ROS. Nature 2011; 472: 476-480.
14. Hoffman JA, Kafatos KC, Janeway CA, et al. Phylogenetic perspectives in innate immunity. Science 1999; 284: 1313-1317.
15. Munford RS,. Sensing Gram-negative bacterial lipopolysaccharides: a human disease determinant? Infect Immun 2008; 76: 454-465.
16. Raetz CR, Whitfield C,. Lipopolysaccharide endotoxins. Annu Rev Biochem 2002; 71: 635-700.
17. Abraham N, Kwon DH,. A single amino acid substituteon in PmrB is associated with polymyxin B resistance in clinical isolate of Pseudomonas aeruginosa. FEMS Microbiol Lett 2009; 298: 249-254.
18. Barrow K, Kwon DH,. Alterations in two-component regulatory systems of phoPQ and pmrAB are associated with polymyxin B resistance in clinical isolates of Pseudomonas aeruginosa. Agents Chemother 2009; 53: 5150-5154.
19. Gunn JS,. Bacterial modifyion of LPS and resistance to antimicrobial peptides. J Endotoxin Res 2001; 7: 57-62.
20. Raetz CR, Reynolds CM, Trent MS, Bishop RE,. Lipid A modifyion systems in Gram-negative bacteria. Annu Rev Biochem 2007; 76: 295-329.
21. Arroyo LA, Fernandez L, Hankins JV, et al. The pmrCAB operon mediates polymyxin resistance in Acinetobacter baumannii ATCC 17987 and clinical isolates through phosphoethanolamine modification of lipid A. Antimicrob Agents Chemother 2011; 55: 3743-3751.
22. Beceiro A, Llobet E, Aranda J, et al. Phosphoethanolamine modification of lipid A in colistin-resistant variants of Acinetobacter baumannii mediated by the pmrAB two-component regulatory system. Antimicrob Agents Chemother 2011; 55: 3370-3379.
23. Rolain JM, Diene SM, Kempf M, et al. Real-time sequencing to decipher the molecular mechanism of resistance of a clinical pan-drug-resistant Acinetobacter baumannii isolate from Marseille, France. Antimicrob Agents Chemother 2013; 57: 592-596.
24. Pelletier MR, Casella LG, Jones JW, et al. Unique structural modifications are present in the lipopolysaccharide from colistin-resistant strains of Acinetobacter baumannii. Antimicrob Agents Chemother 2013; 57: 4831-4840.
25. McPhee JB, Lewenza S, Hancock RE,. Cationic antimicrobial peptides activate a two-component regulatory system, PmrA-PmrB, that regulates resistance to polymyxin B and cationic antimicrobial peptides in Pseudomonas aeruginosa. Mol Microbiol 2003; 50: 205-217.
26. Macfarlane EL, Kwasnicka A, Ochs MM, et al. PhoP-PhoQ homologues in Pseudomonas aeruginosa regulate expression of the outer-membrane protein OprH and polymyxin B resistance. Mol Microbiol 1999; 34: 305-316.
27. Lee JY, Ko KS,. Mutations and expression of PmrAB and PhoPQ related with colistin resistance in Pseudomonas aeruginosa clinical isolates. Diagn Microbiol Infect Dis 2014; 78: 271-276.
28. Moskowitz SM, Brannon MK, Dasgupta N, et al. PmrB mutations promote polymyxin resistance of Pseudomonas aeruginosa isolated from colistin-treated cystic fibrosis patients. Antimicrob Agents Chemother 2012; 56: 1019-1030.
29. Akira S, Uematsu S, Takeuchi O,. Pathogen recognition and innate immunity. Cell 2006; 124: 783-801.
30. Beutler B, Rietschel ET,. Innate immune sensing and its roots: the story of endotoxin. Nature Rev Immunol 2003; 3: 169-176.
31. Calvano SE, Wenzhong X, Rihards DR, et al. A network-based analysis of systemic inflammation in humans. Nature 2005; 473: 1032-1037.
32. Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase I trial of the anti-CD 28 monoclonal antibody TGN1412. New Engl J Med 2006; 355: 1018-1028.
33. Opal SM,. The host response to endotoxin, antilipopolysaccharide strategies, and the management of severe sepsis. Int J Med Microbiol 2007; 297: 365-377.
34. Kobayashi SD, Braughton KR, Whitney AR, et al. Bacterial pathogens modulate an apoptosis differentiation proGram in human neutrophils. Proc Natl Acad Sci 2003; 100: 10948-10953.
35. Molloy EJ,. Triggering receptor expressed on myeloid cells (TREM) family and the application of its antagonists. Rec Pat Antiinfect Drug Discov 2009; 4: 51-56.
36. Martin-Loeches I, Diaz E, Valles J,. Risks for multidrug-resistant pathogens in the ICU. Curr Opin Crit Care 2014; 20: 516-524.
37. Nachtigall I, Tamarkin A, Tafelski S, et al. Polymorphisms of the toll-like receptor 2 and 4 genes are associated with faster progression and a more severe course of sepsis in critically ill patients. J Int Med Res 2013; 42: 93-110.
38. Foster SL, Hargreaves DC, Medzhitov R,. Gene-specific control of inflammation by TLR-induced chromatin modifications. Nature 2007; 477: 972-978.
39. Beceiro A, Tomas M, Bou G,. Antimicrobial resistance and virulence: a successful or deleterious association in the bacterial world? Clin Microbiol Rev 2013; 26: 185-230.
40. Moffatt JH, Harper M, Harrison P, et al. Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production. Antimicrob Agents Chemother 2010; 54: 4971-4977.
41. Henry R, Vithanage N, Harrison P, et al. Colistin-resistant, lipopolysaccharide-deficient Acinetobacter baumannii responds to lipopolysaccharide loss through increased expression of genes involved in the synthesis and transport of lipoproteins, phospholipids, and poly-b-1:6-N-acetylglucosamine. Antimicrob Agents Chemother 2012; 56: 59-69.
42. Adams MD, Nickel GC, Bajaksouzian S, et al. Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system. Antimicrob Agents Chemother 2009; 53: 3628-3634.
43. Lopez-Rojas R, Jimenez-Mejias ME, Lepe JA, et al. Acinetobacter baumannii resistant to colistin alters its antibiotic resistance profile: a case report from Spain. J Infect Dis 2011; 204: 1147-1148.
44. Rolain JM, Roch A, Castanier M, et al. Acinetobacter baumannii resistant to colistin with impaired virulence: a case report from France. J Infect Dis 2011; 204: 1146-1147.
45. Fernandez L, Alvarez-Ortega C, Wiegand I, et al. Characterization of the polymyxin B resistome of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2013; 57: 110-119.
46. Barbe VD, Vallenet N, Fonknechten A, et al. Unique features revealed by the genome sequence of Acinetobacter sp. ADP1, a versatile and naturaly transformation competent bacterium. Nucleic Acids Res 2004; 32: 5766-5779.
47. Gomez MJ, Neyfakh AA,. Genes involved in intrinsic antibiotic resistance of Acinetobacter baylyi. Antimicrob Agents Chemother 2006; 50: 3562-3567.
48. Gooderham WJ, Bains M, McPhee JB, et al. Induction by cationic antimicrobial peptides and involvement in intrinsic polymyxin and antimicrobial peptide resistance, biofilm formation, and swarming motility of PsrA in Pseudomonas aeruginosa. J Bacteriol 2008; 190: 5624-5634.
49. Kitchens RL, Munford RS,. CD14-dependent internalization of bacterial lipopolysaccharide (LPS) is strongly influenced by LPS aggregation but not by cellular responses to LPS. J Immunol 1998; 160: 1920-1928.